Background: The optimal chemotherapy regimen for non-small cell lung cancer patients with interstitial lung disease is unclear. We therefore investigated the safety and efficacy of carboplatin plus nab-paclitaxel as a first-line regimen for non-small cell lung cancer in patients with interstitial lung disease. Methods: We retrospectively reviewed advanced non-small cell lung cancer patients with interstitial lung disease who received carboplatin plus nab-paclitaxel as a first-line chemotherapy regimen at Hyogo Cancer Center between February 2013 and August 2016. interstitial lung disease was diagnosed according to the findings of pretreatment chest high-resolution computed tomography. Results: Twelve patients were included (male, n = 11; female, n = 1). The overall response rate was 67% and the disease control rate was 100%. The median progression free survival was 5.1 months (95% CI: 2.9-8.3 months) and the median overall survival was 14.9 months (95% CI: 4.8-not reached). A chemotherapy-related acute exacerbation of interstitial lung disease was observed in one patient; the extent of this event was Grade 2. There were no treatment-related deaths. Conclusions: Carboplatin plus nab-paclitaxel, as a first-line chemotherapy regimen for nonsmall cell lung cancer, showed favorable efficacy and safety in patients with preexisting interstitial lung disease.
Introduction
The frequency of idiopathic pulmonary fibrosis (IPF) in lung cancer (LC) patients is 2-8% (1). The median survival time (MST) of nonsmall cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) is reported to be 7-16 months (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . However, the prognosis of such patients is poor in comparison to LC patients without ILD because of the limited treatment options. A chemotherapy-induced acute exacerbation (AE) of ILD is potentially fatal, and occurs in 22 .7% of LC patients with ILD (12) . LC patients with ILD have been excluded from most clinical trials. Thus, the optimal chemotherapy regimen for these patients is unclear. To date, several studies have evaluated the safety and efficacy of platinum doublet chemotherapy in NSCLC patients with ILD (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . Minegishi et al. demonstrated the effectiveness of carboplatin plus paclitaxel (PTX) regimen in a prospective trial (2) . Hence, the carboplatin plus paclitaxel regimen is frequently used in the treatment of NSCLC patients with ILD, particularly in Japan.
Nanoparticle albumin-bound (nab) paclitaxel, which binds human serum albumin to PTX, is a nanoparticulate formulation of paclitaxel that can more easily migrate to tumor tissues (13) . In a study of chemotherapy naïve NSCLC patients, the nab-PTX plus carboplatin regimen was associated with a higher objective response rate than PTX plus carboplatin (14) . Thus, nab-PTX is currently approved for the treatment of advanced and metastatic NSCLC in Japan. We hypothesized that carboplatin plus nab-paclitaxel would be a safe and effective first-line regimen for NSCLC in patients with ILD. We therefore retrospectively reviewed the patients who received this regimen at the Hyogo Cancer Center.
Patients and methods

Patients
We retrospectively reviewed advanced NSCLC patients with ILD who received carboplatin plus nab-PTX as a first-line chemotherapy regimen in our hospital between February 2013 and August 2016. ILD was diagnosed based on the findings of pretreatment chest high-resolution computed tomography (HRCT). Two radiologists and a pulmonologist evaluated the chest HRCT scans and divided the ILD patients according to the absence or presence of the UIP pattern based on the ATS/ERS/JRS/ALAT Statement (15) . The definition of the UIP pattern included subpleural, or basal predominance, reticular abnormality, honeycombing with or without traction bronchiectasis and the absence of features inconsistent with the UIP pattern. Staging was determined based on the seventh edition of the TNM classification for lung cancer (16) . We evaluated the Eastern Cooperative Oncology Group (ECOG) performance status (PS), histological pattern, pulmonary function, smoking status and laboratory findings. This study was approved by the Institutional Review Board committee at the Hyogo Cancer Center.
Treatment
The chemotherapy regimen, which was administered in a 21-day cycle, included carboplatin (AUC 6 on Day 1) and nab-PTX (100 mg/m 2 on Days 1, 8 and 15). The decisions to reduce the dose, or omit, or continue chemotherapy were made at the physician's discretion. Chemotherapy was continued until the progression of the disease, the occurrence of intolerable adverse events or until the patient refused treatment. The maximum cycle of platinum doublet chemotherapy was limited to six cycles. Monotherapy with nab-PTX was allowed after at least one cycle of doublet therapy or completion of 4-6 cycles of the platinum doublet chemotherapy.
Evaluation of the response and toxicity
The objective tumor response was evaluated based on the Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST). CT was performed every two cycles during chemotherapy. After completion of chemotherapy, the timing of CT was based on physician's discretion, however, was not more than 3 months. Toxicity was evaluated according to the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE). An AE-ILD was defined by an acute worsening of ILD or the development of dyspnea within 1 month, CT findings showing new bilateral ground-glass opacity and/or consolidation, or deterioration that was not fully explained by cardiac failure or fluid overload (17) . A chemotherapy related AE-ILD was defined as an AE-ILD within 4 weeks from the last day of chemotherapy.
Statistical analysis
Progression free survival (PFS) was defined as the time from the start of chemotherapy until objective tumor progression or death. Overall survival (OS) was defined as the time from the start of chemotherapy until death from any cause. PFS and OS were analyzed using the Kaplan-Meier method. All of the statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University), which is a graphical user interface for the R software program (The R Foundation for Statistical Computing, version 2.13.0) (18) . More precisely, it is a modified version of R commander (version 1.27) that includes statistical functions that are frequently used in biostatistics.
Results
Patient characteristics and clinical information
There were 31 advanced NSCLC patients with ILD during observation period. Of these, 28 patients were received chemotherapy including carboplatin plus nab-PTX, and the remaining three patients were received best supportive care. The study population included 12 patients (male, n = 11; female, n = 1). The clinical characteristics of the 12 patients are summarized in Table 1 . The median age was 73 years. The results of staging, according to seventh edition of the TNM classification for lung cancer, were as follows:
Stage IIIA, n = 1; Stage IIIB, n = 4 and Stage IV, n = 7. The ECOG PS of most patients was 0/1. Three patients showed an UIP pattern on their baseline HRCT scans. All patients were current or former smokers. The histological diagnoses included adenocarcinoma (n = 7), squamous cell carcinoma (n = 4), and NSCLC (n = 1).
Treatment response
The median number of cycles of chemotherapy including monotherapy with nab-PTX was 4 (range, 2-13). Moreover, the median number of cycles of platinum doublet chemotherapy was 4 (range, 2-6). Four patients received monotherapy with nab-PTX during the treatment course. They completed at least four cycles of platinum doublet chemotherapy. There was no case of monotherapy with nab-PTX due to intolerability of platinum doublet chemotherapy. Although the treatment responses were evaluated best responses, there were eight patients with partial response (PR) and four patients with stable disease (SD). The overall response rate (ORR) was 67% and the disease control rate (DCR) was 100%. Of all patients, two patients received second-line chemotherapy, nivolumab and oral S-1, respectively. There was no case of AE-ILD during second-line chemotherapy. However, the objective response of two case was progression disease. The median PFS was 5.1 months (95% CI: 2.9-8.3 months) and the median OS was 14.9 months (95% CI: 4.8-not reached). The Kaplan-Meier curves of PFS and OS are shown in Fig. 1A and B, respectively.
Toxicities
The chemotherapy-related adverse events are summarized in Table 2 . The median relative dose intensity (RDI) of carboplatin was 62.5% (50-100%), and nab-PTX was 49% (20-75%). Moreover, the median RDI of nab-PTX monotherapy was 49% (16-53%). With regard to hematological adverse events, Grade 3 or 4 neutropenia was observed in 83% of the patients (10/12). Febrile neutropenia was observed in one patient. The most common non-hematological adverse events were fatigue, anorexia and rash. Peripheral neuropathy was observed four patients. In one case, treatment was discontinued because of peripheral neuropathy. A chemotherapy-related AE-ILD was observed in one patient; the extent of the adverse event was Grade 2. There were no treatment-related deaths.
Discussion
The results of this study indicate that carboplatin plus nab-PTX could be a treatment option as a first-line chemotherapy regimen for NSCLC patients with ILD. The treatment of NSCLC is rapidly developing, and the overall survival of NSCLC patients has been prolonged with molecular targeted drugs and immune checkpoint inhibitors. However, gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), can induce a chemotherapy related AE-ILD; the incidence of this complication is 5% (19) . Moreover, the incidence associated with the use of nivolumab, an anti-programmed death-1 antibody, is 7% (20) . The incidence of AE-ILDs associated with these drugs is high among NSCLC patients without preexisting ILD. Thus, the platinum doublet regimen achieved favorable results as a first-line chemotherapy regimen for NSCLC patients with ILD.
Several studies, including our own, have investigated the safety and efficacy of platinum doublet regimens for NSCLC patients with ILD (Table 3 ). In the present study the median PFS was 5.1 months (95% CI: 2.9-8.3 months) and the median OS was 14.9 months (95% CI: 4.8-not reached). The PFS and OS of the patients of our study were comparable to those of other studies. Moreover, the OS of our study was not inferior to a Phase III trial (14) . Although the response was evaluated based on the best response, our study showed favorable ORR and DCR values. The severe adverse events (other than AE-ILDs) included neutropenia, leukopenia, thrombocytopenia, anemia and febrile neutropenia. The incidence of neutropenia in our study was consistent with the Japanese subset of the CA031 trial (21) . Unfortunately, an AE-ILD occurred in one patient. The patient was an 80-year-old man with a non-UIP pattern. The AE occurred after the administration of 13 cycles of chemotherapy. The CT findings showed bilateral ground grass opacity and consolidation of the right upper lobe. Bronchoalveolar lavage (BAL) of the right lower lobe was performed. The white blood cell count of the BAL fluid was 300/μl, and the differential cell counts of BAL fluid were as follows: macrophages, 54.2%; lymphocytes, 24.7%; neutrophils, 18.7%; and eosinophils, 1%. Bacterial and acid fast bacillus culturing of the BAL fluid did not yield any organisms. He was treated with methylprednisolone (1 g/day intravenously for 3 days). Thereafter, he was treated with oral prednisolone (50 mg/day). The patient's chest CT findings improved after the initiation of treatment, and the dose of prednisolone was gradually tapered in the outpatient department without a relapse of ILD. The incidence of AE-ILDs in the present study was 8%. Other studies have reported the frequency of chemotherapy related AE-ILDs to be 0-27% (2-11). In the natural course, the 1-year and 3-year incidence rates of AE-ILDs are 14.2% and 20.7%, respectively (22) . Hence, the carboplatin plus nab-PTX regimen is tolerable in terms of safety.
In a Phase II trial, weekly nab-paclitaxel monotherapy was associated with acceptable toxicity and a favorable ORR in previously treated patients with advanced NSCLC. In this trial, the maximum number of chemotherapy cycles was 17 (23) . This trial suggests that the long-term administration of nab-PTX monotherapy is possible. In our study, nab-PTX monotherapy was allowed because this study was retrospective in nature and because it was performed in the clinical setting. Eventually, four patients received nab-PTX monotherapy. An AE-ILD occurred in one of these patients. Thus, the continuation of chemotherapy might increase the risk of an exacerbation. However, there are few available treatment options for LC patients with ILD. We are of the opinion that the continuation of treatment with nab-PTX monotherapy could be a treatment option.
The present study is associated with some limitations, including its retrospective design and the small number of patients. Moreover, we classified the ILD pattern according to the HRCT findings, without surgical lung biopsy or BAL. Kenmotsu et al. reported that the incidence of AE-ILD was significantly higher in LC patients with UIP pattern than in those with non-UIP pattern (24) . Our study included only three NSCLC patients with UIP pattern, therefore, there was a selection bias. In addition, we could not refer to the difference between UIP pattern and non-UIP pattern about AE-ILD during chemotherapy because of small sample size.
In conclusion, carboplatin plus nab-PTX showed favorable efficacy and safety as a first-line chemotherapy regimen for NSCLC patients with preexisting ILD. However, our data were sparse and a prospective case study is warranted to confirm the results. 
